Motexafin gadolinium: A possible new radiosensitiser

Expert Opinion on Investigational Drugs

Volumn 12, Issue 7, 2003, Pages 1205-1210

  Rodrigus, Patrick ^a  

^a DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

Author keywords

Brain metastases; Motexafin gadolinium; Radiosensitiser

Indexed keywords

BLEOMYCIN; CARBON 14; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; GADOLINIUM TEXAPHYRIN; PACLITAXEL; PORPHYRIN DERIVATIVE; RADIOSENSITIZING AGENT;

ABDOMINAL PAIN; ACUTE KIDNEY TUBULE NECROSIS; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; BULLOUS SKIN DISEASE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INTERNATIONAL COOPERATION; LIVER TOXICITY; LUNG CANCER; MAXIMUM PERMISSIBLE DOSE; NAUSEA AND VOMITING; NONHUMAN; OXIDATION REDUCTION REACTION; PARESTHESIA; RADIATION EXPOSURE; RADIOSENSITIZATION; SCLERA DISEASE; SKIN DISCOLORATION; SURVIVAL TIME; TIME; TREATMENT OUTCOME; TUMOR CELL; URINE;

EID: 0038783365     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.7.1205     Document Type: Article

References (21)

1. BEARD CJ, COLEMAN CN, KINSELLA TJ: Radiation sensitizers. In: Cancer: Principles & Practice of Oncology. VT DeVita Jr, S Hellman, SA Rosenberg (Eds), J.B. Lippincott, Philadelphia, USA (1993):2701-2713.
2. WASSERMAN TH, CHAPMAN JD, COLEMAN CN, KLIGERMAN MM: Chemical modifiers of radiation. In: Principles and Practice of Radiation Oncology. CA Peres, Brady LW (Eds), Lippincott-Raven, Philadelphia, USA (1998):685-704.
3. BROWN JM: SR4223 (Tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer (1993) 67:1163-1170.
4. MILLER RA, WOODBURN K, FAN Q, RENSCHLER MF, SESSLER JL, KOUTCHER JA: In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int. J. Radiat. Oncol. Biol. Phys. (1999) 45:981-989.
5. ROCKWELL S, DONNELLY ET, LIU Y, TANG L: Preliminary studies on the effects of gadolineum texaphrin on the growth and radiosensitivity of EMT6 cells in vitro. Int. J. Radiat. Oncol. Biol. Phys. (2002) 54:536-541.
6. XU S, ZAKIAN K, THALER H et al.: Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int. J. Radiat. Oncol. Biol. Phys. (2001) 49(5):1381-1390.
7. MEHTA MP, RODRIGUS P, TERHAARD CHJ et al.: Motexafin Gadolinium prolongs time to neurologic progression in lung cancer patients with brain metastases: results of a randomized Phase III trial. Int. J. Radiat. Oncol. Biol. Phys. (2002) 54:92 (Abstract)
8. MEHTA MP, RODRIGUS P, TERHAARD CHJ et al.: Survival and neurological outcomes in a randomized trial of motexafin Gadolineum and whole brain radiation therapy in brain metasteses. J. Clin. Oncol. (Presented for review).
9. TIMMERMAN B, CARDE P, KOPROWSKI C et al.: Phase IB/II trial of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) for patients with brain metastases: Final results. Int. J. Radiat. Oncol. Biol. Phys. (1998) 42:198 (Abstract).
10. CARDE P, TIMMERMAN R, MEHTA MP et al.: Multicenter Phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J. Clin. Oncol. (2001) 19:2074-2083.
11. VIALA J, VANEL D, MEINGAN P, LARTIGAU E, CARDE P, RENSCHLER M: Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology (1999) 212(3):755-759.
12. SESSLER JL, MILLER RA: Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem. Pharmacol. (2000) 59:733-739.
13. MODY TD, FU L, SESSLER JL: Texaphyrins: synthesis and development of a novel class of therapeutic agents. In: Progress in Inorganic Chemistry. KD Karlin (Ed.), John Wiley & Sons Inc, New York (2001):551-598.
14. YOUNG SW, QING F, HARRIMAN A et al.: Gadolinium (III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl. Acad. Sci. USA (1996) 93:6610-6615.
15. BERNHARDE EJ, MITCHELL JB, DEEN D, CARDELL M, ROSENTHAL DI, BROWN JM: Re-evaluating gadolinium texaphyrin as a radiosensitizing agent. Cancer Res. (2000) 60:86-91.
16. MILLER RA, WOODBURN KW, FAN Q et al.: Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin. Cancer Res. (2001) 7:3215-3221.
17. MAGDA D, LEPP C, GERASIMCHUK N et al.: Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int. J. Radiat. Oncol. Biol. Phys. (2001) 51(4):1025-1036.
18. MAGDA D, GERASIMCHUK N, LECANE P, MILLER RA, BIAGLOW JE, SESSLER JL: Motexafin gadolineum reacts with ascorbate to produce reactive oxygen species. Chem. Commun. (2002)15:2730-2731.
19. MEHTA MP, SHAPIRO WR, GLANTZ MJ et al.: Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J. Clin. Oncol (2002) 20:3445-3453.
20. FORD JM, ENDICOT T, ALDER JR et al.: A Phase I dose escalation trial of motexafin gadolineum as a radiation sensitizer in patients with newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. (2001) 51:205.
21. SUH J, METHA M, CHANG E et al.: Phase II trial of motexafin gadolineum and cranial irradiation in newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. (2002) 54:246 (Abstract).